Evaluation of Novel Hepatitis B DNA Test from Capillary Blood At the Point-of-care As a Tool to Enhance Clinical Management
| Registry | NCT05144776, acronym HBVPOCT |
|---|---|
| Status | Completed |
| Study type | Observational |
| Enrollment | 268 (Actual) |
| Sponsor | Kirby Institute (Other gov) |
| Conditions | Hepatitis B |
| Interventions | GeneXpert HBV DNA Viral Load Assay, Dried Blood Spot HBV DNA test (Diagnostic test) |
| Dates | start 2022-11-17, primary completion 2024-06-01, completion 2024-06-05, first posted 2021-12-03, last updated 2025-03-06 |
| Locations | 6 sites in Australia |
Related Papers Related Patents Related Grants Related Experts
All trials for Hepatitis B All trials of GeneXpert HBV DNA Viral Load Assay All trials of Dried Blood Spot HBV DNA test
This is a cross sectional observational study to asses the performance of two novel HBV DNA testing methodologies; a) dried blood spot sampling and b) fingerstick capillary blood using the Xpert® Hepatitis B Virus viral load assay. Both novel testing methodologies will be compared with venous blood tested using a gold standard HBV DNA assay. The sensitivity and specificity of the two novel testing will be evaluated.
HBV viral load tests are essential to guide antiviral treatment eligibility and effectiveness. However, many people are unable to access these tests, particularly those living in remote or limited resources settings given high cost, or unavailable infrastructure. Simple, affordable and accessible HBV viral load tests are required to increase global access to HBV testing and treatment to meet the WHO HBV elimination targets. The GeneXpert Diagnostic Systems, the most common molecular point-of-care platform globally, has the potential to provide simple and affordable HBV viral load tests. Dried Blood Spot testing is also an affordable and accessible testing methodology particularly suited to remote and resource limited settings. This proof-of-concept study will assess the feasibility and diagnostic performance of Xpert® HBV Viral Load test and Dried Blood Spot testing for the quantitation of HBV DNA from fingerstick capillary samples.
This study will be a cross-sectional observational study and will assess the performance of a novel fingerstick HBV Viral Load and Dried Blood Spot tests within a total of 300 participants who will be recruited across a network of hepatitis clinics in Sydney, Australia. No treatment will be administered as part of this study.
The Xpert HBV cartridge will be adapted to use fingerstick capillary blood instead of processed whole blood, and it's performance measured against a gold standard venous blood HBV DNA assay. Dried Blood Spot HBV DNA testing performance will also be measured against the gold standard venous blood HBV DNA assay.
Secondary objectives of the study are to: 1) evaluate diagnostic performance of the Xpert® HBV Viral Load assay compared to standard of care testing, by patients' hepatitis B e-antigen status (among e-antigen positive and e-antigen negative patients). 2) Evaluate diagnostic performance of the Xpert® HBV Viral Load assay compared to standard of care testing, by HBV treatment status (among treatment naïve patients and those receiving treatment). 3) Evaluate diagnostic performance of the Xpert® HBV Viral Load assay compared to standard of care testing, by HBV DNA levels (among patients with HBV DNA <20 IU/mL; between 20 and 2,000 IU/mL, between 2,000 and 20,000 IU/mL; between 20,000 and 200,000 IU/mL; and >200,000 IU/mL).
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Chronic hepatitis B | Diagnostic Test: GeneXpert HBV DNA Viral Load Assay; Diagnostic Test: Dried Blood Spot HBV DNA test | 300 patients diagnosed with chronic hepatitis B will be enrolled. A fingerstick HBV DNA test will be performed using the Xpert HBV Viral Load assay, and a dried blood spot sample will be collected which will be tested using a gold standard HBV DNA viral load assay. Both results will be compared against the HBV DNA viral load from standard of care venous blood using the gold standard HBV DNA viral load assy. Enrolment of HBV DNA undetectable participants will be capped at 100. |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Have voluntarily signed the informed consent form, 18 years of age or older, HBsAg positive Exclusion Criteria: * Nil
| Facility | City | Country | Status |
|---|---|---|---|
| St Vincent's Hospital | Sydney, New South Wales | Australia | |
| Prince of Wales Hospital | Sydney, New South Wales | Australia | |
| STORR Liver Centre Westmead Hospital | Sydney, New South Wales | Australia | |
| Blacktown Hospital | Sydney, New South Wales | Australia | |
| Liverpool Hospital | Sydney, New South Wales | Australia | |
| St Vincent's Hospital Melbourne | Melbourne, Victoria | Australia |